Cargando…

Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development

Oropouche virus (OROV) is an arthropod-borne orthobunyavirus found in South America and causes Oropouche fever, a febrile infection similar to dengue. It is the second most prevalent arthropod-borne viral disease in South America after dengue. Over 500,000 cases have been diagnosed since the virus w...

Descripción completa

Detalles Bibliográficos
Autores principales: Files, Megan A., Hansen, Clairissa A., Herrera, Vanessa C., Schindewolf, Craig, Barrett, Alan D. T., Beasley, David W. C., Bourne, Nigel, Milligan, Gregg N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931169/
https://www.ncbi.nlm.nih.gov/pubmed/35301331
http://dx.doi.org/10.1038/s41541-022-00456-2
_version_ 1784671197385981952
author Files, Megan A.
Hansen, Clairissa A.
Herrera, Vanessa C.
Schindewolf, Craig
Barrett, Alan D. T.
Beasley, David W. C.
Bourne, Nigel
Milligan, Gregg N.
author_facet Files, Megan A.
Hansen, Clairissa A.
Herrera, Vanessa C.
Schindewolf, Craig
Barrett, Alan D. T.
Beasley, David W. C.
Bourne, Nigel
Milligan, Gregg N.
author_sort Files, Megan A.
collection PubMed
description Oropouche virus (OROV) is an arthropod-borne orthobunyavirus found in South America and causes Oropouche fever, a febrile infection similar to dengue. It is the second most prevalent arthropod-borne viral disease in South America after dengue. Over 500,000 cases have been diagnosed since the virus was first discovered in 1955; however, this is likely a significant underestimate given the limited availability of diagnostics. No fatalities have been reported to date, however, up to 60% of cases have a recurrent phase of disease within one month of recovery from the primary disease course. The main arthropod vector is the biting midge Culicoides paraensis, which has a geographic range as far north as the United States and demonstrates the potential for OROV to geographically expand. The transmission cycle is incompletely understood and vertebrate hosts include both non-human primates and birds further supporting the potential ability of the virus to spread. A number of candidate antivirals have been evaluated against OROV in vitro but none showed antiviral activity. Surprisingly, there is only one report in the literature on candidate vaccines. We suggest that OROV is an undervalued pathogen much like chikungunya, Schmallenberg, and Zika viruses were before they emerged. Overall, OROV is an important emerging disease that has been under-investigated and has the potential to cause large epidemics in the future. Further research, in particular candidate vaccines, is needed for this important pathogen.
format Online
Article
Text
id pubmed-8931169
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-89311692022-04-01 Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development Files, Megan A. Hansen, Clairissa A. Herrera, Vanessa C. Schindewolf, Craig Barrett, Alan D. T. Beasley, David W. C. Bourne, Nigel Milligan, Gregg N. NPJ Vaccines Review Article Oropouche virus (OROV) is an arthropod-borne orthobunyavirus found in South America and causes Oropouche fever, a febrile infection similar to dengue. It is the second most prevalent arthropod-borne viral disease in South America after dengue. Over 500,000 cases have been diagnosed since the virus was first discovered in 1955; however, this is likely a significant underestimate given the limited availability of diagnostics. No fatalities have been reported to date, however, up to 60% of cases have a recurrent phase of disease within one month of recovery from the primary disease course. The main arthropod vector is the biting midge Culicoides paraensis, which has a geographic range as far north as the United States and demonstrates the potential for OROV to geographically expand. The transmission cycle is incompletely understood and vertebrate hosts include both non-human primates and birds further supporting the potential ability of the virus to spread. A number of candidate antivirals have been evaluated against OROV in vitro but none showed antiviral activity. Surprisingly, there is only one report in the literature on candidate vaccines. We suggest that OROV is an undervalued pathogen much like chikungunya, Schmallenberg, and Zika viruses were before they emerged. Overall, OROV is an important emerging disease that has been under-investigated and has the potential to cause large epidemics in the future. Further research, in particular candidate vaccines, is needed for this important pathogen. Nature Publishing Group UK 2022-03-17 /pmc/articles/PMC8931169/ /pubmed/35301331 http://dx.doi.org/10.1038/s41541-022-00456-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Files, Megan A.
Hansen, Clairissa A.
Herrera, Vanessa C.
Schindewolf, Craig
Barrett, Alan D. T.
Beasley, David W. C.
Bourne, Nigel
Milligan, Gregg N.
Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development
title Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development
title_full Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development
title_fullStr Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development
title_full_unstemmed Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development
title_short Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development
title_sort baseline mapping of oropouche virology, epidemiology, therapeutics, and vaccine research and development
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931169/
https://www.ncbi.nlm.nih.gov/pubmed/35301331
http://dx.doi.org/10.1038/s41541-022-00456-2
work_keys_str_mv AT filesmegana baselinemappingoforopouchevirologyepidemiologytherapeuticsandvaccineresearchanddevelopment
AT hansenclairissaa baselinemappingoforopouchevirologyepidemiologytherapeuticsandvaccineresearchanddevelopment
AT herreravanessac baselinemappingoforopouchevirologyepidemiologytherapeuticsandvaccineresearchanddevelopment
AT schindewolfcraig baselinemappingoforopouchevirologyepidemiologytherapeuticsandvaccineresearchanddevelopment
AT barrettalandt baselinemappingoforopouchevirologyepidemiologytherapeuticsandvaccineresearchanddevelopment
AT beasleydavidwc baselinemappingoforopouchevirologyepidemiologytherapeuticsandvaccineresearchanddevelopment
AT bournenigel baselinemappingoforopouchevirologyepidemiologytherapeuticsandvaccineresearchanddevelopment
AT milligangreggn baselinemappingoforopouchevirologyepidemiologytherapeuticsandvaccineresearchanddevelopment